Tiragolumab

Tiragolumab
Monoclonal antibody
Type?
Clinical data
Other namesRG6058, MTIG7192A
Routes of
administration		Intravenous
Drug classImmune checkpoint inhibitor
Identifiers
CAS Number
UNII
KEGG
ChEBI
Chemical and physical data
FormulaC6620H10206N1742O2074S40
Molar mass148664.99 g·mol−1

Tiragolumab (development names RG6058 and MTIG7192A) is a humanized monoclonal antibody that functions as an immune checkpoint inhibitor by targeting the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) pathway. Developed by Genentech and Roche, the drug is designed to enhance anti-tumor immune responses when used in combination with other immunotherapy agents, particularly atezolizumab (Tecentriq).

In January 2021, tiragolumab received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for use in combination with atezolizumab in the treatment of patients with PD-L1-high metastatic non-small-cell lung cancer (NSCLC) who do not harbor EGFR mutations or ALK rearrangements.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.